Letters to the editor
Non-selective β-adrenoceptor blockers in patients with decompensated liver disease
Editor – We read with great interest the excellent article ‘Drug therapies in liver disease’ by Collins et al (Clin Med December 2013 pp 585–91). However, the section regarding the use of β-blockers warrants further comment.
Although the use of non-selective β-adrenoceptor blockers is strongly supported in the use of primary and secondary prophylaxis of variceal bleeding,1 there has been some controversy with its use in patients with advanced cirrhosis. In a study by Serste et al,2 151 patients with Child Pugh C cirrhosis and refractory ascites were assessed. Seventy-seven patients were being treated with β-blockers and 74 were not. At 1 year, 19% of patients treated with β-blockers were alive, compared to 64% who were not (p < 0.0001). A follow-up study by the same group found that inpatients with refractory ascites and on β-blockers had a higher risk of paracentesis-induced circulatory dysfunction.
Admittedly the studies have flaws and robust randomised controlled trials are needed, but clinicians should be cautious when using these drugs in patients with advanced liver disease.
Footnotes
Please submit letters for the editor's consideration within three weeks of receipt of Clinical Medicine. Letters should ideally be limited to 350 words, and sent by email to: clinicalmedicine{at}rcplondon.ac.uk
- © 2014 Royal College of Physicians
References
Article Tools
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.